Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20015797HPVENSG00000141736.14protein_codingERBB2YesNo2064F5H1T4
J3QLU9
P04626
X5DNK3
TVIS20015088HPVENSG00000141736.14protein_codingERBB2YesNo2064F5H1T4
J3QLU9
P04626
X5DNK3
TVIS20015081HPVENSG00000141736.14protein_codingERBB2YesNo2064F5H1T4
J3QLU9
P04626
X5DNK3
TVIS20015090HPVENSG00000141736.14protein_codingERBB2YesNo2064F5H1T4
J3QLU9
P04626
X5DNK3
TVIS20015094HPVENSG00000141736.14protein_codingERBB2YesNo2064F5H1T4
J3QLU9
P04626
X5DNK3
TVIS20030932HPVENSG00000141736.14protein_codingERBB2YesNo2064F5H1T4
J3QLU9
P04626
X5DNK3
TCGA Plot Options
Drug Information
GeneERBB2
DrugBank IDDB15035
Drug NameZanubrutinib
Target IDBE0000511
UniProt IDP04626
Regulation Typeinhibitor
PubMed IDs31340982; 31381333
CitationsTam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW: Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24.@@Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F, Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z: Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. J Med Chem. 2019 Sep 12;62(17):7923-7940. doi: 10.1021/acs.jmedchem.9b00687. Epub 2019 Aug 19.
GroupsApproved; Investigational
Direct ClassificationDiphenylethers
SMILESNC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1
Pathways
PharmGKB
ChEMBLCHEMBL3936761